Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma –affected patients
DiscussionOur results show that, in patients with B-cell lymphoma under rituximab therapy, anti–SARS-CoV-2 mRNA vaccination induces a weak or absent humoral response but a consistent T-cell response. In addition, chemotherapy regimens with bendamustine further reduce patients’ ability to mount a Spike-specific humoral response even after a long time period from chemotherapy discontinuation. These results provide evidence that different chemotherapeutics display different immunosuppressive properties that could be taken in to account in the choice of the right drug regimen for the right patient. Moreover, they question ...
Source: Frontiers in Immunology - December 1, 2023 Category: Allergy & Immunology Source Type: research
EE666 Cost-Effectiveness of Duvelisib Versus the Bendamustine Plus Rituximab Regimen for Relapsed/Refractory Follicular Lymphoma Patients in China
To assess the cost-effectiveness of duvelisib compared to the bendamustine plus rituximab (BR) regimen for treating adult patients with relapsed/refractory follicular lymphoma (RR FL) who have undergone at least two lines of prior therapy in Chinese healthcare setting. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: L. Chen, B. Tan, X. Gao, K. Zhou, J. Zhao, J. Xuan Source Type: research
EE517 Cost-Effectiveness Analysis of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Greece
Tafasitamab is indicated in combination with lenalidomide followed by tafasitamab monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). We sought to evaluate the cost-effectiveness of tafasitamab and lenalidomide combination followed by tafasitamab monotherapy versus polatuzumab vedotin, bendamustine and rituximab (Pola-BR), tisagenlecleucel, and rituximab, gemcitabine and oxaliplatin (R-GemOx) from a Greek third-party payer perspective. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Karaiskou, A. Avgitidou, Z. Vostitsanou, M. Batsi, G. Bungey, T. Prawitz, B. Peter, P. Stafylas Source Type: research
EE209 Can the German Efficiency Frontier Approach Support Decision-Making Processes for Pricing New Medicines? An Application to Second-Line Interventions of Transplant-Ineligible Diffuse Large B-Cell Lymphoma
For patients with diffuse large B-cell lymphoma (DLBCL), treatment options (interventions) are limited if their disease relapses or is refractory (r/r) to first-line therapy and they are ineligible for stem cell transplantation. Innovative interventions have been recently approved by the European Medicine Agency (tafasitamab-lenalidomide, Tafa-L; polatuzumab-bendamustine-rituximab, Pola-BR) for second-line (2L) treatment addressing this unmet medical need. Further interventions, e.g., CAR-T-cell therapies, are expected to be introduced for the 2L soon, albeit at rising treatment costs. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M.S. Kurte, A.C. Siefen, F. Jakobs, B. von Tresckow, H.C. Reinhardt, F. Kron Source Type: research
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of < em > TP53 < /em > mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group
Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.283724. Online ahead of print.ABSTRACTBetween 2011 and 2012, a phase II trial evaluated the use of the RiBVD (Rituximab, Bendamustine, Velcade and Dexamethasone) combination as first-line treatment for mantle cell lymphoma (MCL) patients aged over 65. We have now re-examined the classic prognostic factors, adding an assessment of the mutation status of TP53. Patients (n=74; median age 73 years) were treated with the RiBVD combination. Median Progression Free Survival (mPFS) was 79 months, and median Overall Survival (mOS) was 111 months. TP53 mutation status was availa...
Source: Haematologica - November 30, 2023 Category: Hematology Authors: Sylvain Carras Alexia Torroja Anouk Emadali Emilie Montaut Nicolas Daguindau Adrian Tempescul Anne Moreau Emmanuelle Tchernonog Anna Schmitt Roch Houot Caroline Dartigeas Sarah Barbieux Selim Corm Anne Banos Ludovic Fouillet Jehan Dupuis Margaret Macro Jo Source Type: research
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of < em > TP53 < /em > mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group
Haematologica. 2023 Nov 30. doi: 10.3324/haematol.2023.283724. Online ahead of print.ABSTRACTBetween 2011 and 2012, a phase II trial evaluated the use of the RiBVD (Rituximab, Bendamustine, Velcade and Dexamethasone) combination as first-line treatment for mantle cell lymphoma (MCL) patients aged over 65. We have now re-examined the classic prognostic factors, adding an assessment of the mutation status of TP53. Patients (n=74; median age 73 years) were treated with the RiBVD combination. Median Progression Free Survival (mPFS) was 79 months, and median Overall Survival (mOS) was 111 months. TP53 mutation status was availa...
Source: Haematologica - November 30, 2023 Category: Hematology Authors: Sylvain Carras Alexia Torroja Anouk Emadali Emilie Montaut Nicolas Daguindau Adrian Tempescul Anne Moreau Emmanuelle Tchernonog Anna Schmitt Roch Houot Caroline Dartigeas Sarah Barbieux Selim Corm Anne Banos Ludovic Fouillet Jehan Dupuis Margaret Macro Jo Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clin Med Res - November 20, 2023 Category: Research Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
